Published in Clin Cancer Res on November 04, 2013
Progress in central nervous system lymphomas. Br J Haematol (2014) 0.96
Drug delivery systems, CNS protection, and the blood brain barrier. Biomed Res Int (2014) 0.95
The Challenge of Primary Central Nervous System Lymphoma. Hematol Oncol Clin North Am (2016) 0.77
Complement activation and rituximab distribution in CNS NHL--letter. Clin Cancer Res (2015) 0.75
Reply to M.C. Chamberlain. J Clin Oncol (2014) 0.75
New approaches in primary central nervous system lymphoma. Chin Clin Oncol (2015) 0.75
Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res (1998) 4.87
Modulation of the antitumor immune response by complement. Nat Immunol (2008) 4.53
Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med (2009) 4.11
Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med (2012) 3.61
Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J Neurosci (2001) 3.23
Rituximab: mechanism of action. Semin Hematol (2010) 2.66
Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol (2007) 2.64
The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci (2012) 2.53
Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood (2002) 2.28
Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina (2006) 2.23
Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood (2010) 2.08
Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol (2007) 2.07
Gene expression and angiotropism in primary CNS lymphoma. Blood (2006) 1.79
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood (2007) 1.69
Intraventricular administration of BDNF increases the number of newly generated neurons in the adult olfactory bulb. Mol Cell Neurosci (1998) 1.61
Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann N Y Acad Sci (2003) 1.60
Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer (2001) 1.60
Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol (2004) 1.59
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood (2012) 1.58
C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation. J Immunol (2009) 1.41
Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol (2008) 1.38
Microglia/macrophage-specific protein Iba1 binds to fimbrin and enhances its actin-bundling activity. J Neurochem (2004) 1.29
Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol (2011) 1.28
Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica (2004) 1.23
Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res (2010) 1.22
Deletion of the complement anaphylatoxin C3a receptor attenuates, whereas ectopic expression of C3a in the brain exacerbates, experimental autoimmune encephalomyelitis. J Immunol (2004) 1.21
High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol (2008) 1.17
Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Mult Scler (2008) 1.17
Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res Treat (2009) 1.14
Central nervous system involvement in diffuse large B-cell lymphoma. Eur J Haematol (2010) 1.11
Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anticancer Drugs (2008) 1.08
Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood (2012) 1.07
Complement activation as a biomarker for Alzheimer's disease. Immunobiology (2011) 1.04
Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma (2001) 1.02
Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Clin Cancer Res (2009) 0.98
Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma. J Neurooncol (2006) 0.98
Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis. Ann Pharmacother (2010) 0.97
Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol (2012) 0.96
Rituximab penetrates full-thickness retina in contrast to tissue plasminogen activator control. Retina (2007) 0.95
Intrathecal rituximab treatment for pediatric post-transplant lymphoproliferative disorder of the central nervous system. Pediatr Blood Cancer (2008) 0.95
Complement C3a enhances CXCL12 (SDF-1)-mediated chemotaxis of bone marrow hematopoietic cells independently of C3a receptor. J Immunol (2005) 0.94
Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann Oncol (2009) 0.91
Increased production of the third component of complement (C3) by monocytes from patients with systemic lupus erythematosus. Clin Exp Immunol (1990) 0.90
Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy. Br J Haematol (2008) 0.90
Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant. Pediatr Blood Cancer (2011) 0.88
Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder. Leuk Lymphoma (2012) 0.86
Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab. Leuk Lymphoma (2008) 0.86
Neuroprotection from complement-mediated inflammatory damage. Ann N Y Acad Sci (2004) 0.86
Rapid complete response using intrathecal rituximab in a patient with leptomeningeal lymphomatosis due to mantle cell lymphoma. Anticancer Drugs (2008) 0.84
Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab. Cancer Chemother Pharmacol (2008) 0.80
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. Clin Cancer Res (2011) 0.80
Hepatitis B virus reactivation in a primary central nervous system lymphoma patient following intrathecal rituximab treatment. Acta Haematol (2010) 0.79
Genome sequencing in microfabricated high-density picolitre reactors. Nature (2005) 150.21
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol (2009) 9.67
Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell (2011) 7.30
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell (2010) 5.77
Global diversity in the human salivary microbiome. Genome Res (2009) 5.16
Metabolite identification via the Madison Metabolomics Consortium Database. Nat Biotechnol (2008) 5.12
Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA. Cell Res (2011) 4.55
Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol (2003) 4.44
Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate. Sci Transl Med (2013) 4.23
Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A (2008) 4.14
IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest (2008) 4.12
Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol (2011) 4.09
Modification of kidney barrier function by the urokinase receptor. Nat Med (2007) 4.01
Exchange-coupled nanocomposite magnets by nanoparticle self-assembly. Nature (2002) 3.71
Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs. Nat Immunol (2006) 3.68
Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science (2003) 3.60
Dectin-1 activates Syk tyrosine kinase in a dynamic subset of macrophages for reactive oxygen production. Blood (2005) 3.57
The histone H3K4 demethylase SMCX links REST target genes to X-linked mental retardation. Nature (2007) 3.55
Syk is required for integrin signaling in neutrophils. Immunity (2002) 3.39
Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med (2011) 3.19
Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science (2013) 3.17
Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet (2010) 3.15
The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci U S A (2004) 3.15
Transfusion-related acute lung injury: incidence and risk factors. Blood (2011) 3.12
Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest (2009) 3.08
Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. Nat Immunol (2005) 2.97
Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton. J Cell Biol (2002) 2.92
Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol (2008) 2.92
Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol (2012) 2.83
The ins and outs of leukocyte integrin signaling. Annu Rev Immunol (2009) 2.76
Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol (2006) 2.76
Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. Immunity (2008) 2.67
Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol (2007) 2.56
Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients. J Infect Dis (2012) 2.53
Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci U S A (2003) 2.50
Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion-related acute lung injury. J Clin Invest (2006) 2.50
Spleen tyrosine kinase Syk is necessary for E-selectin-induced alpha(L)beta(2) integrin-mediated rolling on intercellular adhesion molecule-1. Immunity (2007) 2.43
N-Benzyl-2-(2,6-dichloro-phen-oxy)-acetamide. Acta Crystallogr Sect E Struct Rep Online (2008) 2.36
Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J Am Soc Nephrol (2006) 2.32
Control of the pattern-recognition receptor EFR by an ER protein complex in plant immunity. EMBO J (2009) 2.28
Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood (2002) 2.28
Histone demethylase UTX-1 regulates C. elegans life span by targeting the insulin/IGF-1 signaling pathway. Cell Metab (2011) 2.22
High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology (2002) 2.22
Chronic stimulation of Nod2 mediates tolerance to bacterial products. Proc Natl Acad Sci U S A (2007) 2.20
Project management system for structural and functional proteomics: Sesame. J Struct Funct Genomics (2003) 2.19
New bioinformatics resources for metabolomics. Pac Symp Biocomput (2007) 2.19
Regulation of human airway epithelial cell IL-8 expression by MAP kinases. Am J Physiol Lung Cell Mol Physiol (2002) 2.19
Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology (2009) 2.15
Effects of vacuum-assisted closure on wound microcirculation: an experimental study. Asian J Surg (2005) 2.14
A sphingosine-1-phosphate-activated calcium channel controlling vascular smooth muscle cell motility. Circ Res (2006) 2.12
Generation of functional ion-channel tools by E3 targeting. Nat Biotechnol (2005) 2.08
The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp Diabetes Res (2009) 2.08
Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol (2007) 2.07
Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematologica (2007) 2.07
Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist (2011) 2.05
Reducing personal exposure to particulate air pollution improves cardiovascular health in patients with coronary heart disease. Environ Health Perspect (2012) 2.05
Learning brain connectivity of Alzheimer's disease by sparse inverse covariance estimation. Neuroimage (2010) 2.04
Essential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell development. Nat Immunol (2003) 2.04
A phosphorylation state-specific antibody recognizes Hsp27, a novel substrate of protein kinase D. J Biol Chem (2005) 2.03
Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem (2003) 2.01
Expression of midkine and endoglin in breast carcinomas with different immunohistochemical profiles. APMIS (2010) 2.00
Effect of otitis media with effusion and its clinical intervention on the development of mastoid in children. Acta Otolaryngol (2014) 1.98
TRPC channel activation by extracellular thioredoxin. Nature (2008) 1.97
The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity (2010) 1.97
The multifaceted functions of neutrophils. Annu Rev Pathol (2013) 1.97
Cloning and characterization of mouse E2F8, a novel mammalian E2F family member capable of blocking cellular proliferation. J Biol Chem (2005) 1.95
Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci U S A (2009) 1.94
Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcepsilonRI. Proc Natl Acad Sci U S A (2003) 1.94
Thermal difference spectra: a specific signature for nucleic acid structures. Nucleic Acids Res (2005) 1.91
Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology (2002) 1.90
Adult-onset drug-refractory seizure disorder associated with anti-voltage-gated potassium-channel antibody. Epilepsia (2009) 1.88
Peritumoral diffusion tensor imaging of high-grade gliomas and metastatic brain tumors. AJNR Am J Neuroradiol (2003) 1.87
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol (2008) 1.84
Dynamic contrast-enhanced perfusion MR imaging measurements of endothelial permeability: differentiation between atypical and typical meningiomas. AJNR Am J Neuroradiol (2003) 1.83
Src and Syk kinases: key regulators of phagocytic cell activation. Trends Immunol (2005) 1.81
Using spatial principles to optimize distributed computing for enabling the physical science discoveries. Proc Natl Acad Sci U S A (2011) 1.81
A conserved Tyr residue is required for sugar selectivity in a Pol alpha DNA polymerase. Biochemistry (2002) 1.81
Distinct roles for neutrophils and dendritic cells in inflammation and autoimmunity in motheaten mice. Immunity (2013) 1.80
Chinese authors do need CONSORT: reporting quality assessment for five leading Chinese medical journals. Contemp Clin Trials (2008) 1.80
HIV incidence among men who have sex with men in China: a meta-analysis of published studies. PLoS One (2011) 1.79
PSGL-1 engagement by E-selectin signals through Src kinase Fgr and ITAM adapters DAP12 and FcR gamma to induce slow leukocyte rolling. J Exp Med (2008) 1.79
Impaired integrin-dependent function in Wiskott-Aldrich syndrome protein-deficient murine and human neutrophils. Immunity (2006) 1.79
Differential transformation capacity of Src family kinases during the initiation of prostate cancer. Proc Natl Acad Sci U S A (2011) 1.76
Chlorophyllase 1, a damage control enzyme, affects the balance between defense pathways in plants. Plant Cell (2004) 1.76
Extracellular protein disulfide isomerase regulates ligand-binding activity of αMβ2 integrin and neutrophil recruitment during vascular inflammation. Blood (2013) 1.75
EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One (2011) 1.73
Beta-AMYLASE4, a noncatalytic protein required for starch breakdown, acts upstream of three active beta-amylases in Arabidopsis chloroplasts. Plant Cell (2008) 1.72
Proliferation and differentiation of bone marrow stromal cells under hypoxic conditions. Biochem Biophys Res Commun (2006) 1.72
Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells. Immunity (2011) 1.72
The WRKY family of transcription factors in rice and Arabidopsis and their origins. DNA Res (2005) 1.70
Discussion of fertility preservation with newly diagnosed patients: oncologists' views. J Cancer Surviv (2007) 1.68
Neutrophils mediate antibody-induced antitumor effects in mice. Blood (2013) 1.66
Drosophila Rae1 controls the abundance of the ubiquitin ligase Highwire in post-mitotic neurons. Nat Neurosci (2011) 1.66
Metagenome-wide analysis of antibiotic resistance genes in a large cohort of human gut microbiota. Nat Commun (2013) 1.65
A mixed-valence copper coordination polymer generated by hydrothermal metal/ligand redox reactions. Chem Commun (Camb) (2002) 1.65
Common variants in P2RY11 are associated with narcolepsy. Nat Genet (2010) 1.65
Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes Dev (2012) 1.64
Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg (2012) 1.64